Comparative Pharmacology
Head-to-head clinical analysis: DIUPRES 500 versus HYDRA ZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUPRES 500 versus HYDRA ZIDE.
DIUPRES-500 vs HYDRA-ZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diupres-500 is a combination of chlorothiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid. Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion. Reserpine depletes catecholamines from central and peripheral nerve terminals by blocking vesicular monoamine transporter 2 (VMAT2), leading to decreased sympathetic outflow and vasodilation.
Hydra-Zide is a combination of hydrochlorothiazide (thiazide diuretic) and hydralazine (direct vasodilator). Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing electrolyte reabsorption and increasing urine output. Hydralazine relaxes arteriolar smooth muscle, decreasing systemic vascular resistance and afterload.
Oral, 1 tablet (hydrochlorothiazide 50 mg + reserpine 0.125 mg) once daily, increased up to 2 tablets per day if needed.
Oral, 1 tablet (25 mg hydrochlorothiazide / 50 mg hydralazine) twice daily, titrated up to maximum of 2 tablets twice daily based on blood pressure response.
None Documented
None Documented
Reserpine: 50-100 hours (prolonged; clinical effect persists for days due to irreversible MAO depletion). Hydrochlorothiazide: 6-15 hours (biphasic; terminal phase reflects renal elimination).
Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); thiazide: 6-15 hours.
Renal: ~50% (primarily hydrochlorothiazide), Fecal: ~50% (primarily reserpine).
Renal: 50-70% of hydralazine as metabolites, 30-40% as parent drug; thiazide: 95% renal as unchanged drug.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination